What is Function Oncology?
Function Oncology is at the forefront of personalized functional genomics, leveraging CRISPR technology to deliver differentiated insights into patients and diseases. The company's platform enables efficient, scalable, and individualized assessment of target vulnerabilities directly within clinical samples. This innovative approach aims to identify therapeutic opportunities previously inaccessible and to power the development of novel therapies against critical, often hidden, disease drivers, ultimately driving better patient outcomes.
How much funding has Function Oncology raised?
Function Oncology has raised a total of $28M across 1 funding round:
Series A
$28M
Series A (2023): $28M with participation from Section 32 and Casdin Capital
Key Investors in Function Oncology
Section 32
Section 32 is a venture capital firm known for investing in cutting-edge technology and supporting visionary entrepreneurs. Their focus on innovative startups and emerging technologies aligns with Function Oncology's advanced genomics approach.
Casdin Capital
Casdin Capital brings deep expertise and a long-term perspective to financing life science innovation, with a notable portfolio in diagnostics and molecular information, indicating a strong strategic interest in Function Oncology's field.
What's next for Function Oncology?
With this substantial strategic investment, Function Oncology is poised to accelerate its platform development and expand its reach in the precision medicine market. The company's focus on actionable insights derived from functional genomics suggests a trajectory towards clinical integration and therapeutic development partnerships. This capital infusion will likely fuel further research, enhance its technological capabilities, and support the scaling of its operations to meet the growing demand for personalized cancer therapies.
See full Function Oncology company page
